Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer
Executive Summary
The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.
You may also be interested in...
Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval
As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.
Lupin’s Pegfilgrastim Biosimilar Accepted By US FDA
Lupin’s first US biosimilar application, for a rival to Neulasta, has been accepted for filing by the FDA. If approved, the product would join an already crowded market for pegfilgrastim in the US.